Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Med Chem ; 116: 222-238, 2016 Jun 30.
Article in English | MEDLINE | ID: mdl-27061986

ABSTRACT

In a previous communication we reported on the discovery of alkylamino pyridine derivatives (e.g. 1) as a new class of potent, selective and efficacious S1P1 receptor (S1PR1) agonists. However, more detailed profiling revealed that this compound class is phototoxic in vitro. Here we describe a new class of potent S1PR1 agonists wherein the exocyclic nitrogen was moved away from the pyridine ring (e.g. 11c). Further structural modifications led to the identification of novel alkylaminomethyl substituted phenyl and thienyl derivatives as potent S1PR1 agonists. These new alkylaminomethyl aryl compounds showed no phototoxic potential. Based on their in vivo efficacy and ability to penetrate the brain, the 5-alkyl-aminomethyl thiophenes appeared to be the most interesting class. Potent and selective S1PR1 agonist 20e, for instance, maximally reduced the blood lymphocyte count (LC) for 24 h after oral administration of 10 mg/kg to rat and its brain concentrations reached >500 ng/g over 24 h.


Subject(s)
Drug Design , Pyridines/chemistry , Pyridines/pharmacology , Receptors, Lysosphingolipid/agonists , Animals , Brain/metabolism , Male , Pyridines/chemical synthesis , Pyridines/pharmacokinetics , Rats , Rats, Wistar , Structure-Activity Relationship
2.
J Med Chem ; 57(1): 110-30, 2014 Jan 09.
Article in English | MEDLINE | ID: mdl-24367923

ABSTRACT

In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P1 agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P1 agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P1 agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P1 and S1P3 receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.


Subject(s)
Pyridines/chemical synthesis , Receptors, Lysosphingolipid/agonists , Thiophenes/chemical synthesis , Animals , Brain/metabolism , Male , Pyridines/pharmacokinetics , Pyridines/pharmacology , Rats , Rats, Wistar , Structure-Activity Relationship , Thiophenes/pharmacokinetics , Thiophenes/pharmacology
3.
J Med Chem ; 57(1): 78-97, 2014 Jan 09.
Article in English | MEDLINE | ID: mdl-24345087

ABSTRACT

Previously, we reported on the discovery of a novel series of bicyclo[3.1.0]hexane fused thiophene derivatives that serve as potent and selective S1P1 receptor agonists. Here, we discuss our efforts to simplify the bicyclohexane fused thiophene head. In a first step the bicyclohexane moiety could be replaced by a simpler, less rigid cyclohexane ring without compromising the S1P receptor affinity profile of these novel compounds. In a second step, the thiophene head was simplified even further by replacing the cyclohexane ring with an isobutyl group attached either to position 4 or position 5 of the thiophene. These structurally much simpler headgroups again furnished potent and selective S1P1 agonists (e.g., 87), which efficiently and dose dependently reduced the number of circulating lymphocytes upon oral administration to male Wistar rats. For several compounds discussed in this report lymphatic transport is an important route of absorption that may offer opportunities for a tissue targeted approach with minimal plasma exposure.


Subject(s)
Bridged Bicyclo Compounds/chemical synthesis , Receptors, Lysosphingolipid/agonists , Thiophenes/chemical synthesis , Animals , Bridged Bicyclo Compounds/chemistry , Bridged Bicyclo Compounds/pharmacology , Humans , Male , Rats , Rats, Wistar , Structure-Activity Relationship , Thiophenes/pharmacology
4.
J Med Chem ; 56(23): 9737-55, 2013 Dec 12.
Article in English | MEDLINE | ID: mdl-24266709

ABSTRACT

From a high-throughput screening campaign aiming at the identification of novel S1P1 receptor agonists, the pyrazole derivative 2 emerged as a hit structure. Medicinal chemistry efforts focused not only on improving the potency of the compound but in particular also on resolving its inherent instability issue. This led to the discovery of novel bicyclo[3.1.0]hexane fused thiophene derivatives. Compounds with high affinity and selectivity for S1P1 efficiently reducing the blood lymphocyte count in the rat were identified. For instance, compound 85 showed EC50 values of 7 and 2880 nM on S1P1 and S1P3, respectively, had favorable pharmacokinetic properties in rat and dog, distributed well into brain tissue, and efficiently and dose dependently reduced the blood lymphocyte count in the rat. After oral administration to spontaneously hypertensive rats, the S1P1 selective compound 85 showed no effect on mean arterial blood pressure and affected the heart rate during the wake phase of the animals only.


Subject(s)
Pyrazoles/chemical synthesis , Receptors, Lysosphingolipid/agonists , Thiophenes/chemical synthesis , Animals , Dogs , Drug Stability , Lymphocyte Count , Lysophospholipids/metabolism , Pyrazoles/pharmacokinetics , Pyrazoles/pharmacology , Rats , Sphingosine/analogs & derivatives , Sphingosine/metabolism , Structure-Activity Relationship , Thiophenes/pharmacokinetics , Thiophenes/pharmacology
5.
J Med Chem ; 53(10): 4198-211, 2010 May 27.
Article in English | MEDLINE | ID: mdl-20446681

ABSTRACT

Sphingosine-1-phosphate (S1P) is a widespread lysophospholipid which displays a wealth of biological effects. Extracellular S1P conveys its activity through five specific G-protein coupled receptors numbered S1P(1) through S1P(5). Agonists of the S1P(1) receptor block the egress of T-lymphocytes from thymus and lymphoid organs and hold promise for the oral treatment of autoimmune disorders. Here, we report on the discovery and detailed structure-activity relationships of a novel class of S1P(1) receptor agonists based on the 2-imino-thiazolidin-4-one scaffold. Compound 8bo (ACT-128800) emerged from this series and is a potent, selective, and orally active S1P(1) receptor agonist selected for clinical development. In the rat, maximal reduction of circulating lymphocytes was reached at a dose of 3 mg/kg. The duration of lymphocyte sequestration was dose dependent. At a dose of 100 mg/kg, the effect on lymphocyte counts was fully reversible within less than 36 h. Pharmacokinetic investigation of 8bo in beagle dogs suggests that the compound is suitable for once daily dosing in humans.


Subject(s)
Imines/chemical synthesis , Receptors, Lysosphingolipid/agonists , Thiazoles/chemical synthesis , Thiazolidines/chemical synthesis , Administration, Oral , Animals , Cell Line , Cricetinae , Cricetulus , Dogs , Hepatocytes/metabolism , High-Throughput Screening Assays , Humans , Imines/pharmacokinetics , Imines/pharmacology , Lymphocyte Count , Male , Microsomes, Liver/metabolism , Radioligand Assay , Rats , Rats, Wistar , Stereoisomerism , Structure-Activity Relationship , Thiazoles/pharmacokinetics , Thiazoles/pharmacology , Thiazolidines/pharmacokinetics , Thiazolidines/pharmacology
6.
J Pharmacol Exp Ther ; 311(1): 204-12, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15146030

ABSTRACT

Urotensin-II (U-II) is a cyclic peptide now described as the most potent vasoconstrictor known. U-II binds to a specific G protein-coupled receptor, formerly the orphan receptor GPR14, now renamed urotensin receptor (UT receptor), and present in mammalian species. Palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt) is a new potent and specific antagonist of the human UT receptor. ACT-058362 antagonizes the specific binding of (125)I-labeled U-II on natural and recombinant cells carrying the human UT receptor with a high affinity in the low nanomolar range and a competitive mode of antagonism, revealed only with prolonged incubation times. ACT-058362 also inhibits U-II-induced calcium mobilization and mitogen-activated protein kinase phosphorylation. The binding inhibitory potency of ACT-058362 is more than 100-fold less on the rat than on the human UT receptor, which is reflected in a pD'(2) value of 5.2 for inhibiting contraction of isolated rat aortic rings induced by U-II. In functional assays of short incubation times, ACT-058362 behaves as an apparent noncompetitive inhibitor. In vivo, intravenous ACT-058362 prevents the no-reflow phenomenon, which follows renal artery clamping in rats, without decreasing blood pressure and prevents the subsequent development of acute renal failure and the histological consequences of ischemia. In conclusion, the in vivo efficacy of the specific UT receptor antagonist ACT-058362 reveals a role of endogenous U-II in renal ischemia. As a selective renal vasodilator, ACT-058362 may be effective in other renal diseases.


Subject(s)
Quinolines/pharmacology , Receptors, G-Protein-Coupled/antagonists & inhibitors , Urea/analogs & derivatives , Urea/pharmacology , Urotensins/metabolism , Vasoconstriction/drug effects , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/physiology , Disease Models, Animal , Humans , Ischemia/complications , Kidney Diseases/metabolism , Kidney Diseases/physiopathology , Male , Quinolines/chemistry , Rats , Rats, Wistar , Renal Insufficiency/physiopathology , Urea/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...